RxSight, Inc.
RXST
$25.84
$0.622.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.71% | 59.08% | 67.65% | 68.75% | 77.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.71% | 59.08% | 67.65% | 68.75% | 77.65% |
| Cost of Revenue | 4.58% | 19.20% | 20.94% | 23.92% | 26.08% |
| Gross Profit | 63.07% | 83.67% | 101.83% | 99.55% | 137.86% |
| SG&A Expenses | 33.19% | 33.76% | 33.14% | 43.32% | 33.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.86% | 28.32% | 25.51% | 31.37% | 26.88% |
| Operating Income | 20.49% | 26.26% | 38.84% | 18.53% | 27.61% |
| Income Before Tax | 35.55% | 49.00% | 56.00% | 31.19% | 41.08% |
| Income Tax Expenses | 166.67% | 8.33% | -38.46% | -- | -460.00% |
| Earnings from Continuing Operations | 35.29% | 48.95% | 55.96% | 31.12% | 41.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.29% | 48.95% | 55.96% | 31.12% | 41.21% |
| EBIT | 20.49% | 26.26% | 38.84% | 18.53% | 27.61% |
| EBITDA | 17.22% | 29.19% | 40.48% | 21.31% | 30.35% |
| EPS Basic | 42.36% | 54.24% | 60.48% | 40.85% | 54.24% |
| Normalized Basic EPS | 42.55% | 48.42% | 59.48% | 40.92% | 54.13% |
| EPS Diluted | 42.36% | 54.24% | 60.48% | 40.85% | 54.24% |
| Normalized Diluted EPS | 42.55% | 48.42% | 59.48% | 40.92% | 54.13% |
| Average Basic Shares Outstanding | 12.22% | 11.57% | 11.47% | 16.46% | 28.48% |
| Average Diluted Shares Outstanding | 12.22% | 11.57% | 11.47% | 16.46% | 28.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
